Suresh S. Ramalingam, MD, an internationally recognized lung cancer physician-investigator, has been named Deputy Director of Winship Cancer Institute of Emory University. He will also serve as Assistant Dean for Cancer Research in the Emory School of Medicine.
In his role as Winship’s Deputy Director, Dr. Ramalingam will lead the integration of the research, clinical, and educational components within Winship. This position was previously held by Fadlo R. Khuri, MD, who assumed the presidency of American University of Beirut in August 2015.
Dr. Ramalingam, Professor in Emory’s Department of Hematology and Medical Oncology, now serves as Winship’s Director of Medical Oncology and its Lung Cancer Program. He currently co-leads Winship’s Discovery and Developmental Therapeutics Program.
Board certified in medical oncology and internal medicine, Dr. Ramalingam chairs the Thoracic Malignancies Committee and serves as Deputy Chair for the Therapeutics Program within ECOG-ACRIN [Eastern Cooperative Oncology Group–American College of Radiology Imaging Network], a National Cancer Institute–supported national clinical trials group. His research focuses on agents that inhibit pathways for specific lung cancer mutations. He is also investigating ways to individualize therapies in patients with small cell and non–small cell lung cancer.
Dr. Ramalingam has authored over 200 scientific publications and is the Section Editor for “chest diseases” for the journal Cancer. He is on the editorial boards of the Journal of Clinical Oncology, Annals of Oncology, and Clinical Lung Cancer.
Dr. Ramalingam is a graduate of Kilpauk Medical College at the University of Madras in Madras, India. He completed his residency in internal medicine at Wayne State University and his fellowship in hematology and medical oncology at the University of Pittsburgh Cancer Institute. ■